Risk of Fracture in Primary Aldosteronism: A Population-Based Cohort Study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Primary aldosteronism (PA) is associated with increased urinary calcium excretion and osteoporosis prevalence. We studied the long-term effect of hyperaldosterone on fracture risk and possible risk mitigation via treatments, by comparing PA patients and their essential hypertension (EH) counterparts extracted by propensity score match. We used a longitudinal population database from the Taiwan National Health Insurance, and used a validated algorithm to identify PA patients diagnosed in 1997–2010. Our sample included 2533 PA patients, including 921 patients with aldosterone-producing adenoma (APA). Our methods for assessing excessive fracture risk included multivariable Cox regression and the competing risk regression. The incidence rate of fracture at any site was 14.4 per 1000 person-years for PA, and 11.2 per 1000 person-years for APA. In contrast, the incidence rate of fracture at any site was 8.3 per 1000 person-years in EH controls for PA, and 6.5 per 1000 person-years in EH controls for APA. Mineralocorticoid receptor antagonist (MRA) treatment might be associated with higher risk of osteoporotic fracture in the whole female PA cohort (subdistribution hazard ratio [SHR] = 2.12, p = 0.008) as well as female APA patients (SHR = 1.15, p = 0.049). As to fracture at any site, MRA treatment was also associated with higher risk; the SHR was 1.88 (p < 0.001) in the whole female PA cohort, and 2.17 (p = 0.019) in female APA patients. PA is tightly associated with higher risk of bone fracture, even in the case where the competing risk of death was controlled. Particularly, female PA patients treated with MRA were confronted with significantly higher risk in bone fracture than their EH controls. © 2017 American Society for Bone and Mineral Research. Abstract Our research provides the first evidence on primary aldosteronism (PA)-related long-term risk in bone fracture from a large population-based cohort and under a study design of case-control match on propensity score. PA is tightly associated with higher risk of bone fracture, even in the case where the competing risk of death was controlled. Particularly, female PA patients treated with MRA were confronted with significantly higher risk in bone fracture than their essential hypertensive controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 4×
“Identification of APA patients was on the basis of the following criteria: (1) receiving the diagnosis of adrenal tumor (ICD code: 227, 227.”
BackgroundMethodInfluentialRossi, E., Sani, C., Perazzoli, F., Casoli, M. C., Negro, A., & Dotti, C. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00182-o · Cited by 134
Bone involvement in aldosteronism
Salcuni, A. S., Palmieri, S., Carnevale, V., Morelli, V., Battista, C., Guarnieri, V., Guglielmi, G., Desina, G., Eller-Vainicher, C., Beck-Peccoz, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1660 · Cited by 101
Primary Hyperparathyroidism With Concurrent Primary Aldosteronism
Maniero, C., Fassina, A., Guzzardo, V., Lenzini, L., Amadori, G., Pelizzo, M. R., Gomez-Sanchez, C., & Rossi, G. P. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.173948 · Cited by 94 · cited 1×
“PTH is further increased as a result of the MR-mediated calciuretic and magnesiuretic, and secondary hyperparathyroidism causes disturbed bone metabolism.((21)) Therefore, the calciuresis in prolonged hyperaldosterone would represent a continuous stimulus to increased PTH secretion, which further induced a progressive…”
BackgroundFracture Risk in Men With Congestive Heart Failure
Carbone, L. D., Cross, J. D., Raza, S. H., Bush, A. J., Sepanski, R. J., Dhawan, S., Khan, B. Q., Gupta, M., Ahmad, K., Khouzam, R. N., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.039 · Cited by 79
Cited by
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
Adler, G. K., Stowasser, M., Correa, R. R., Khan, N., Kline, G., McGowan, M. J., Mulatero, P., Murad, M. H., Touyz, R. M., Vaidya, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf284 · Cited by 355
Diagnosis and treatment of primary aldosteronism
Reincke, M., Bancos, I., Mulatero, P., Scholl, U. I., Stowasser, M., & Williams, T. A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00210-2 · Cited by 354
Diagnosis and treatment of primary aldosteronism: practical clinical perspectives
Young, W. F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12831 · Cited by 325
Vaidya, A., Mulatero, P., Baudrand, R., & Adler, G. K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00139 · Cited by 299
Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
Arlt, W., Lang, K., Sitch, A. J., Dietz, A. S., Rhayem, Y., Bancos, I., Feuchtinger, A., Chortis, V., Gilligan, L. C., Ludwig, P., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93136 · Cited by 281
Metadata
- Authors
- Wu, V.-C., Chang, C.-H., Wang, C.-Y., Lin, Y.-H., Kao, T.-W., Lin, P.-C., Chu, T.-S., Chang, Y.-S., Chen, L., Wu, K.-D., & Chueh, S.-C. J.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-11-10
- Volume
- 32
- Issue
- 4
- Pages
- 743-752
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2549741543
- Cited by
- 81
- References
- 5
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.